» Articles » PMID: 35432942

Cell Penetrating Peptide Decorated Magnetic Porous Silicon Nanorods for Glioblastoma Therapy and Imaging

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 Apr 18
PMID 35432942
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme (GBM) is the most malignant primary brain tumor of the central nervous system. Despite advances in therapy, it remains largely untreatable, in part due to the low permeability of chemotherapeutic drugs across the blood-brain barrier (BBB) which significantly compromises their effectiveness. To circumvent the lack of drug efficiency, we designed multifunctional nanoparticles based on porous silicon. Herein, we propose an innovative synthesis technique for porous silicon nanorods (pSiNRs) with three-dimensional (3D) shape-controlled nanostructure. In order to achieve an efficient administration and improved treatment against GBM cells, a porous silicon nanoplatform is designed with magnetic guidance, fluorescence tracking and a cell-penetrating peptide (CPP). A NeuroFilament Light (NFL) subunit derived 24 amino acid tubulin binding site peptide called NFL-TBS.40-63 peptide or NFL-peptide was reported to preferentially target human GBM cells compared to healthy cells. Motivated by this approach, we investigated the use of magnetic-pSiNRs covered with superparamagnetic iron oxide nanoparticles (SPIONs) for magnetic guidance, then decorated with the NFL-peptide to facilitate targeting and enhance internalization into human GBM cells. Unexpectedly, under confocal microscope imaging, the internalized multifunctional nanoparticles in GBM cells induce a remarkable exaltation of green fluorescence instead of the red native fluorescence from the dye due to a possible Förster resonance energy transfer (FRET). In addition, we showed that the uptake of NFL-peptide decorated magnetic-pSiNRs was preferential towards human GBM cells. This study presents the fabrication of magnetic-pSiNRs decorated with the NFL-peptide, which act as a remarkable candidate to treat brain tumors. This is supported by results and confocal imaging.

Citing Articles

Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective.

Milewska S, Sadowska A, Stefaniuk N, Misztalewska-Turkowicz I, Wilczewska A, Car H Int J Mol Sci. 2024; 25(11).

PMID: 38892406 PMC: 11172452. DOI: 10.3390/ijms25116219.


Passing of Nanocarriers across the Histohematic Barriers: Current Approaches for Tumor Theranostics.

Gareev K, Tagaeva R, Bobkov D, Yudintceva N, Goncharova D, Combs S Nanomaterials (Basel). 2023; 13(7).

PMID: 37049234 PMC: 10096980. DOI: 10.3390/nano13071140.


Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.

Liu Y, Zhao Z, Li M Asian J Pharm Sci. 2022; 17(4):523-543.

PMID: 36105313 PMC: 9458999. DOI: 10.1016/j.ajps.2022.05.002.


Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Duskey J, Rinaldi A, Ottonelli I, Caraffi R, De Benedictis C, Sauer A Pharmaceutics. 2022; 14(7).

PMID: 35890345 PMC: 9325049. DOI: 10.3390/pharmaceutics14071450.

References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Zhou J, Patel T, Sirianni R, Strohbehn G, Zheng M, Duong N . Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 2013; 110(29):11751-6. PMC: 3718184. DOI: 10.1073/pnas.1304504110. View

3.
Kang R, Jang J, Huh E, Kang S, Ahn D, Kang J . A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma. Nanoscale Horiz. 2020; 5(8):1213-1225. DOI: 10.1039/d0nh00077a. View

4.
Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Biasibetti E . Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies. J Pharm Sci. 2014; 103(7):2157-2165. DOI: 10.1002/jps.24002. View

5.
Mo J, He L, Ma B, Chen T . Tailoring Particle Size of Mesoporous Silica Nanosystem To Antagonize Glioblastoma and Overcome Blood-Brain Barrier. ACS Appl Mater Interfaces. 2016; 8(11):6811-25. DOI: 10.1021/acsami.5b11730. View